首页> Molecular therapy : the journal of the American Society of Gene Therapy> An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

导出 OA

翻译打印收藏纠错

第一作者： Benjamin,Vesin

第一单位： Pasteur-TheraVectys Joint Lab, Institut Pasteur, Virology Department, 28 rue du Dr. Roux, Paris F-75015, France.

作者： Benjamin,Vesin ^[1] ; Jodie,Lopez ^[1] ; Amandine,Noirat ^[1] ; Pierre,Authié ^[1] ; Ingrid,Fert ^[1] ; Fabien,Le Chevalier ^[1] ; Fanny,Moncoq ^[1] ; Kirill,Nemirov ^[1] ; Catherine,Blanc ^[1] ; Cyril,Planchais ^[2] ; Hugo,Mouquet ^[2] ; Françoise,Guinet ^[3] ; David,Hardy ^[4] ; Francina Langa,Vives ^[5] ; Christiane,Gerke ^[6] ; François,Anna ^[1] ; Maryline,Bourgine ^[1] ; Laleh,Majlessi ^[7] ; Pierre,Charneau ^[1]

作者单位： Pasteur-TheraVectys Joint Lab, Institut Pasteur, Virology Department, 28 rue du Dr. Roux, Paris F-75015, France. ^[1] Laboratory of Humoral Immunology, Université de Paris, Immunology Department, Institut Pasteur, INSERM U1222, Paris F-75015, France. ^[2] Lymphocytes and Immunity Unit, Université de Paris, Immunology Department, Institut Pasteur, Paris F-75015, France. ^[3] Histopathology Platform, Institut Pasteur, Paris F-75015, France. ^[4] Mouse Genetics Engineering, Institut Pasteur, Paris F-75015, France. ^[5] Institut Pasteur, Université de Paris, Innovation Office, Vaccine Programs, Institut Pasteur, Paris F-75015, France. ^[6] Pasteur-TheraVectys Joint Lab, Institut Pasteur, Virology Department, 28 rue du Dr. Roux, Paris F-75015, France. Electronic address: laleh.majlessi@pasteur.fr. ^[7]

关键词 SARS-CoV-2 emerging variants of concern intranasal vaccination lentiviral vaccine mucosal booster vaccine mucosal immunity waning anti-COVID-19 immunity